Search Results
Your search for ,itS matches 8761 pages
Showing 1351 - 1400ACCC Releases Advocacy Agenda at 49th Annual Meeting & Cancer Center Business Summit
The Association of Community Cancer Centers (ACCC) represents members nationwide from all care delivery settings. ACCC’s 49th Annual Meeting & Cancer Business Summit was held March 8–10, 2023, in Washington, DC, where the society released its advocacy agenda for 2023. Areas of Focus ACCC...
Early Exposure to Health-Care Inequities Sets the Stage for a Leadership Role in Global Oncology for Satish Gopal, MD, MPH
In this installment of The ASCO Post’s Global Oncology series, guest editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Satish Gopal, MD, MPH, Director of the Center for Global Health at the National Cancer Institute (NCI). In this role, he oversees the development of initiatives and...
Cleveland Clinic Opens New Cancer Center in Abu Dhabi
Cleveland Clinic has announced the opening of a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi. “[This] marks the next step in fulfilling our mission to provide compassionate, complex care in the United Arab Emirates [UAE)]” said Tom...
A Pioneering Oncologist, a Pilot, and a Choral Singer, Among Other Things
“There is and always has been, more to me than medicine. Ever since the university, I have loved flying. Ever since school, I have adored choral singing,” writes John F. Smyth, MD, in his memoir Taming the Beast: Memoirs of a Pioneering Cancer Physician. Dr. Smyth is Emeritus Professor of Medical...
Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
Patricia M. LoRusso, DO, PhD (hc), Elected 2023–2024 AACR President-Elect
The members of the American Association for Cancer Research (AACR) have elected Patricia M. LoRusso, DO, PhD (hc), as the President-Elect for the 2023 to 2024 term. Dr. LoRusso will become President-Elect on Monday, April 17, during the Annual Business Meeting of Members at the AACR Annual Meeting...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Report Examines Accuracy of ChatGPT in Providing Information on Common Cancer Myths and Misconceptions
In the first study of its kind, researchers evaluated the reliability and accuracy of ChatGPT’s cancer information, as chatbots and artificial intelligence (AI) have become popular resources. A report published by Johnson et al in JNCI Cancer Spectrum summarized the accuracy of the tool in...
Retroperitoneal Lymph Node Dissection for Early Metastatic Testicular Seminoma
In a phase II trial reported in the Journal of Clinical Oncology, Daneshmand et al found that first-line retroperitoneal lymph node dissection (RPLND) was associated with good outcomes in patients with testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy. As stated by the...
Cancer Diagnostic Services Offered at a Community Health Center May Speed Diagnoses for Underserved Patients
In a new colocation model for cancer diagnostic services, researchers have found that a new program installed at a community health center that cares for historically underserved populations was able to reduce the time to cancer diagnosis from a median of 32 days to 12 days, according to an article ...
ACCC Releases 2022 Impact Report
The Association of Community Cancer Centers (ACCC)—which represents more than 34,000 multidisciplinary oncology practitioners—outlined successful programs and initiatives in 2022 that advanced oncology care, according to the ACCC's 2022 Impact Report. These new programs and initiatives included...
Does Discrimination Accelerate Aging in Black Cancer Survivors?
Investigators have found that Black cancer survivors who reported high levels of discrimination showed greater biological aging and frailty than those who reported lower levels of discrimination, according to a new study published by Mandelblatt et al in the journal Cancer. Background...
Study Reveals Potential Cause of Resistance to Revumenib in Patients With Acute Myeloid Leukemia
Use of the novel menin inhibitor revumenib has led to remissions in patients with acute myeloid leukemia (AML), and associated findings have suggested the mechanisms through which cancer cells may become resistant to such treatment, according to two studies published by Issa et al and Perner et al, ...
Axitinib and Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma
In a single-center phase II trial reported in the Journal of Clinical Oncology, Renata Ferrarotto, MD, and colleagues found that the combination of axitinib and avelumab showed evidence of activity in patients with recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 28...
Vitamin A and Risk for Pancreatitis During Chemotherapy for ALL
Consuming a diet rich in vitamin A or its analogs may help prevent pediatric and young adult patients with acute lymphoblastic leukemia (ALL) reduce their risk of developing pancreatitis during chemotherapy, according to a recent study by Tsai et al in Science Translational Medicine. Background For ...
Large Study Finds Digital Breast Tomosynthesis May Be Superior to Digital Mammography for Breast Cancer Detection
In a study of over a million patients, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results were published by Conant et al in Radiology. Breast cancer screening with two-dimensional (2D) digital...
Novel Urine Test May Play a Role in Bladder Cancer Prediction
Testing for genetic mutations in urine may help clinicians detect bladder cancer years before the disease shows clinical symptoms, according to new findings presented by Le Calvez-Kelm et al at the 2023 European Association of Urology Annual Congress (Abstract A0268). The researchers identified...
FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants
On March 8, the U.S. Food and Drug Administration (FDA) provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue, or capsule, that forms around breast implants. Previously, on September 8, 2022, the FDA released a safety communication informing the public of reports of...
Trends in Active Surveillance for Management of Low-Risk Prostate Cancer in the United States
In an analysis reported in JAMA Network Open, Cooperberg et al found that the use of active surveillance (AS) for low-risk prostate cancer in U.S. patients has more than doubled in recent years but remains suboptimal and exhibits wide variations at the urology practice and individual practitioner...
I’m Doing My Part to Erase the Stigma Surrounding Lung Cancer
Ironically, I received a diagnosis of lung cancer when I was feeling my healthiest. In December 2015, when I was just 51 years old, a routine chest x-ray found a small shadow on the lower lobe of my right lung. Despite being a never-smoker, a regular exerciser, and a healthy eater, my primary care...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
FDA Updates Mammography Regulations to Require Reporting of Breast Density Information and Enhance Facility Oversight
On March 9, the U.S. Food and Drug Administration (FDA) published updates to the mammography regulations to, among other things, require mammography facilities to notify patients about the density of their breasts, strengthen the FDA’s oversight and enforcement of facilities, and help interpreting...
Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO and the Association for Clinical Oncology, issued the following statement after President Joseph Biden’s State of the Union address on February 7. “ASCO applauds President Biden’s focus on ‘ending cancer as ...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Radiation Oncology Workforce Expected to Remain Stable Through 2030, According to ASTRO Report
After analyzing the U.S. radiation oncology workforce, investigators projected a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030, according to an American Society for Radiation Oncology (ASTRO) Workforce Taskforce review...
Blood Test May Identify Patients With AML at Greater Risk of Relapse After Bone Marrow Transplant
Researchers have found that screening for residual disease prior to a bone marrow transplant may help physicians identify which adult patients in remission from acute myeloid leukemia (AML) are at risk of relapsing after the procedure, according to a novel study published by Dillon et al in JAMA....
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
Hormone Therapy May Reduce Risk of Lung Cancer in Female Patients, Despite Former Misperceptions
Investigators have demonstrated that, despite some commonly held misperceptions, hormone therapy doesn’t increase patients’ risk of developing lung cancer—and it could help reduce the risk, according to a 16-year population-based study published by Wu et al in Menopause. The findings may help...
Cancer Organizations Respond to Turkey and Syria Earthquakes
On February 6, 2023, a powerful 7.8-magnitude earthquake, followed by a second 7.5-magnitude quake, struck southeast Turkey and northwest Syria. To date, the quakes and several major aftershocks have killed nearly 52,000 citizens—more than 45,000 in Turkey and more than 6,700 in Syria—and injured...
Black Women at High Risk of Breast Cancer May Face Obstacles in Receiving Preventive Care
Black women at high risk of developing breast cancer may face a variety of obstacles keeping them from receiving preventive care that could increase their chances of survival if they did develop the disease, according to a new study published by Padamsee et al in PLOS One. The new findings provide...
Vitamin B5 May Help Improve Red Blood Cell Production in Patients With Myelodysplastic Syndromes
Researchers have discovered that vitamin B5 in combination with existing drugs may be the key to improving outcomes in patients with myelodysplastic syndromes (MDS) and ineffective red blood cell production, according to a novel study published by Mian et al in Science Translational Medicine....
Immunotherapy Costs May Drive Increase in Medicare Spending for Outpatient End-of-Life Cancer Care
Researchers have discovered that recent increases in Medicare spending on outpatient end-of-life cancer care may have been driven almost entirely by costs associated with immunotherapy, which is given to fewer than one in five patients, according to a new study published by Mantz et al in the...
Mediterranean Diet and Immune Checkpoint Blockade Outcomes in Advanced Melanoma
In the PRIMM study reported in JAMA Oncology, Bolte et al found that consumption of a Mediterranean diet was associated with a high probability of objective response and 12-month progression-free survival among patients receiving immune checkpoint blockade treatment for advanced melanoma. As stated ...
Millions of U.S. Individuals May Have Missed Cancer Screenings During Second Year of COVID-19 Pandemic
Investigators have found that millions of individuals in the United States continued to miss critical cancer screening tests during the second year of the COVID-19 pandemic, according to a new study published by Star et al in the Journal of Clinical Oncology. Compared with 2019 levels, individuals...
New Study Demonstrates Inferior Vena Cava Filters May Be Safe and Effective Way to Prevent Venous Thromboembolism
Researchers have discovered that few adverse events may be associated with the use of inferior vena cava filters to help prevent deep vein thrombosis from developing into pulmonary embolisms, according to a new study jointly published by Johnson et al in the Journal of Vascular and Interventional...
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
ASCO Endorses CAP Guideline to Better Define Who Benefits From Immune Checkpoint Inhibitor Therapy
ASCO has endorsed a new guideline from the College of American Pathologists (CAP) on the use of mismatch repair (MMR) and microsatellite instability (MSI) testing, which could help oncologists more accurately identify patients who may be suitable candidates for immune checkpoint inhibitor ...
Expert Point of View: Adam M. Brufsky, MD
Commenting on the study from Tata Memorial Centre for The ASCO Post, Adam M. Brufsky, MD, Professor of Medicine, Associate Chief of the Division of Hematology/Oncology and Co-Director of the Comprehensive Breast Cancer Center at the University of Pittsburgh School of Medicine, noted that the...
Expert Point of View: Laura Goff, MD, MSCI
Invited discussant Laura Goff, MD, MSCI, Associate Professor of Medicine and Executive Medical Director for the Cancer Patient Care Center at Vanderbilt-Ingram Cancer Center, Nashville, said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic...
First-Line NALIRIFOX Improves Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine.1 NALIRIFOX, which contains liposomal irinotecan, fluorouracil,...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Understanding the Health Disparities That Sexual and Gender Minorities Face in Oncology Care
In its programming for the 2022 ASCO Annual Meeting, ASCO included a special Education Session on “Gender-Based and Sexual Orientation Inequities: Promoting Inclusion, Visibility, and Data Accuracy in Oncology.” The session offered a comprehensive discussion on the challenges that sexual and gender ...
Expert Point of View: Dustin Deming, MD
The invited discussant of the SUNLIGHT trial, Dustin Deming, MD, the ACI/Schwenn Family Association Professor in the Division of Hematology, Medical Oncology, and Palliative Care and Director of JD Fluno Colorectal Cancer Precision Medicine at the University of Wisconsin, Madison, said the findings ...
Neighborhood Social Vulnerability and Its Influence on the Availability of Clinical Trials in Multiple Myeloma
Clinical trials set the treatment standards for cancer care. However, for select populations, such as those who are older, Black, or facing socioeconomic challenges, access to clinical trials and health care generally remains limited. Barriers to clinical trial participation are numerous and...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
Adding Talazoparib to Enzalutamide Extends Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
Intensified Drug Regimen Added to Standard of Care Improves Outcomes in Subset of Patients With High-Risk Prostate Cancer
In the phase III FORMULA-509 trial, the addition of abiraterone acetate/prednisone and apalutamide—compared with bicalutamide—to salvage radiation therapy plus 6 months of treatment with a gonadotropin-releasing hormone (GnRH) agonist failed to improve progression-free survival postprostatectomy in ...
Brexucabtagene Autoleucel in Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice
In an analysis from the U.S. Lymphoma CAR T Consortium reported in the Journal of Clinical Oncology, Wang et al found that standard-of-care treatment with brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma since its approval in this setting has been associated with response...
TALAPRO-2: Talazoparib Plus Enzalutamide Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The TALAPRO-2 phase III clinical trial found that combining the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib with the androgen receptor inhibitor enzalutamide resulted in significantly better progression-free survival vs the current standard of care for patients with metastatic...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
